ORCL is up +10.63% in Wednesday's regular session to about $144.40, after closing at $130.53 the prior day. The primary catalyst was Oracle's investor day, where CFO Hilary Maxson guided to positive free cash flow in H2 fiscal 2028 and at least $30 billion in fiscal 2029—far above forecasts that expected continued negative cash flow.

ELVA is trading up +10.92% during regular market hours, near $5.79 versus a prior close of $5.22. Primary catalyst: a strategic supply agreement with Janus Electric, including roughly $26 million in initial lithium-ion battery purchase orders for Class 8 truck electrification.

EVR shares are up +11.73% to about $290.34, adding +$30.48 from the prior session's close of $259.86, with the surge beginning in premarket trading and holding through the regular session. The move was driven by a blowout Q3 2026 report: adjusted EPS of $4.28 crushed the $2.48 consensus (+72.9%), while record net revenue of $1.17 billion beat the ~$925 million estimate.

ANTX gained +12.69% to $4.35, with the move extending during regular market hours after premarket news. Primary catalyst: positive enabling data supporting advancement of oral AN2-502998 to a Phase 2 study in chronic Chagas disease, with 100% parasite clearance in naturally infected non-human primates.

BLMN jumped +10.79% during regular market hours, trading near $10.06 versus a $9.08 prior-session close. The primary catalyst was renewed optimism around the Outback Steakhouse turnaround, with fresh coverage citing improved H1 net income, EBITDA growth, and net-debt reduction.

Schrödinger (SDGR) rose +13.44% during regular trading to roughly $30.31, up from a prior close of $26.72. The move had no company-specific catalyst and tracked a broad rally in AI-driven drug-discovery names (Absci +12%, Recursion +9%).

FLXS is up +13.37% (+$9.01 to $76.40) during the regular session, rebounding from Monday's $67.39 close. The move follows a sharp -18.36% drop on Oct 27, when shares sold off despite Q1 EPS of $1.24 and $114M revenue beating estimates.

WING jumped +13.6% during regular market hours to about $140.32, up from a prior close of $123.52, after Q3 results beat estimates. The primary catalyst was an earnings beat: adjusted EPS of $1.08 topped the $1.02 consensus, though revenue of $185.1M missed and domestic same-store sales fell -5.4%.

BEAM climbed roughly +13.8% intraday during Wednesday's regular session, trading near $28.34 versus a $24.90 prior close. The move extends Tuesday's +4.67% gain driven by initial Phase 1/2 BEAM-301 data showing proof-of-concept in GSDIa — median fasting time rose from 2.5 to 15 hours, with two 40 mg patients off starch.

WEN surged +14.98% to $7.06, up from the prior session's close of $6.14. The rally hit at the opening bell during regular trading after reports that Nelson Peltz's Trian Fund Management made a roughly $1.4 billion cash take-private offer.

CUE is up +18.23% during regular market hours, climbing from a $18.32 prior close to roughly $21.66 intraday. The advance came in the regular session, extending the stock's recent volatility as a micro-cap biotech.

VRT surged +15.67% to $241.24 during regular trading, up from a prior close of $208.56. The catalyst was a Q3 beat-and-raise: revenue rose +61% to $4.31 billion and adjusted EPS of $2.21, both well above estimates, with organic orders more than doubling year-over-year.

REPL gained +18.70% during regular market hours, rising from a $13.05 prior close to about $15.49. The move followed fiscal Q2 results: a loss of $0.54 per share beat consensus by $0.24, and R&D and SG&A expenses fell year over year.

Ginkgo Bioworks (DNA) climbed +19.34% to $13.45, up +$2.18 from its prior close of $11.27. The gain occurred during regular market hours, extending a rebound that has lifted shares roughly +120% over the past month.

PRME shares climbed +19.54% during regular trading on Wednesday, advancing from a $4.35 prior close to roughly $5.20 and touching a 52-week high. The primary catalyst: Prime Medicine dosed the first patient in its Phase 1/2 trial of PM577a, its in vivo prime editor for Wilson disease.

NKLR shares rose +6.6% to $2.26 during regular market hours, versus a $2.12 prior-session close. The gain came even as B. Riley cut its price target to $8 from $10 while keeping a Buy rating, still implying roughly +277% upside.

FVN rose +8.16% to $12.06 during regular market hours, up from the prior session's $11.15 close. The advance extends a volatile stretch for this low-float, Shanghai-based SPAC, which recently resumed trading after a volatility pause.

GMAB surged +32.59% to $59.23 in regular trading, up from the prior close of $44.67. Catalyst: positive Phase 3 LiGeR-HN1 topline results showing petosemtamab plus pembrolizumab cut the risk of death by 50% in first-line PD-L1-positive head and neck cancer.

INTG is trading up +7.52% (+$2.62) to $37.45 during the regular session, versus a prior close of $34.83. No company-specific news or SEC filing was released today; the move appears driven by thin-volume, low-float momentum rather than a fundamental catalyst.

NAUT is trading up +9.69% during regular market hours, rising from a $2.89 prior close to about $3.17. The gain extends follow-through buying after yesterday's Q3 earnings beat: EPS of -$0.12 versus -$0.14 expected and revenue of $230K versus $206K.